Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain

• Published in: Ophthalmology and therapy Vol. 13; no. 7; pp. 1937 - 1953
• Main Authors: Ruiz-Moreno, José M., Gámez Lechuga, María, Calvo, Pilar, Merino, María, Martín Lorenzo, Teresa, Maravilla-Herrera, Paulina, Gil Jiménez, Beatriz, Abraldes, Maximino J.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.07.2024; Adis, Springer Healthcare
• Subjects: Burden of disease; DMO; Healthcare costs; Internal Medicine; Medicine; Medicine & Public Health; Non-healthcare costs; Ophthalmology; Original Research; Productivity losses; Resource consumption; Productivity losses; Resource consumption; Healthcare costs; DMO; Burden of disease; Non-healthcare costs; Quality of life
• ISSN: 2193-8245; 2193-6528
• DOI: 10.1007/s40123-024-00959-2

Introduction Diabetic macular oedema (DMO) is a complication of diabetic retinopathy that can result in vision loss. The disease can impact different spheres of a patient’s life, including physical and psychological health, work, and activities of daily living, entailing an important use of healthcare and non-healthcare resources. This study aimed to estimate the socio-economic burden of DMO in Spain. Methods The burden of DMO was estimated from a societal perspective, per patient, year of treatment since diagnosis, and type of treatment. Four categories were considered: direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labour productivity losses (LPL), and intangible costs (IC) associated with loss of quality of life. Average annual costs were calculated by multiplying the resources used per patient by their corresponding unit price (or financial proxy). For a more accurate estimation, differences in resource use between treatments (intravitreal anti-vascular endothelial growth factor injections of ranibizumab or aflibercept, and intravitreal dexamethasone implants) and year since diagnosis (first, second, and third year or beyond) were considered and presented separately. The reference year for costs was 2021. Results The average annual costs of DMO in the first year of treatment after diagnosis was estimated at €18,774, €17,512, and €16,188 per patient treated with ranibizumab, aflibercept, and dexamethasone, respectively. This burden would be reduced to €15,783, €15,701, and €12,233 in the second year, and to €15,119, €15,043, and €12,790 in the third year, respectively. Diagnosis of DMO entails an additional one-off cost of €485. DHC accounted for the greatest proportion of total annual costs per patient, independent of the year, with LPL also making an important contribution to total costs. Conclusions The socio-economic impact of DMO on patients, the healthcare system, and society at large is substantial. The constant increase in its prevalence accentuates the need for planning and implementation of healthcare strategies to prevent vision loss and reduce the socio-economic burden of the disease.